Evogene (EVGN)
(Delayed Data from NSDQ)
$2.70 USD
+0.01 (0.37%)
Updated Sep 20, 2024 03:58 PM ET
After-Market: $2.69 -0.01 (-0.37%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Evogene Ltd falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 31 | 35 | 54 | 48 | 47 |
Receivables | 3 | 2 | 3 | 4 | 2 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 1 | 0 | 0 | 0 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 |
Total Current Assets | 34 | 38 | 57 | 52 | 49 |
Net Property & Equipment | 2 | 3 | 2 | 2 | 3 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 13 | 14 | 15 | 16 | 17 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 51 | 56 | 76 | 72 | 71 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 1 | 1 | 1 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 3 | 2 | 3 | 3 | 2 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2 | 2 | 2 | 6 | 2 |
Total Current Liabilities | 7 | 6 | 7 | 10 | 6 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 15 | 15 | 4 | 4 | 3 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 22 | 21 | 13 | 15 | 11 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 269 | 261 | 260 | 225 | 206 |
Retained Earnings | -258 | -234 | -207 | -179 | -156 |
Other Equity | 17 | 7 | 10 | 11 | 10 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 29 | 35 | 63 | 57 | 60 |
Total Liabilities & Shareholder's Equity | 51 | 56 | 76 | 72 | 71 |
Total Common Equity | 29 | 35 | 63 | 57 | 60 |
Shares Outstanding | 4.10 | 4.10 | 2.50 | 2.50 | 2.50 |
Book Value Per Share | 7.00 | 8.49 | 25.37 | 22.75 | 24.09 |
Fiscal Year End for Evogene Ltd falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 21 | 27 | 31 | 37 | 34 |
Receivables | 4 | 4 | 3 | 3 | 2 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 1 | 1 | 0 | 0 | 0 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 |
Total Current Assets | 26 | 31 | 34 | 41 | 36 |
Net Property & Equipment | 2 | 2 | 2 | 3 | 3 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 13 | 13 | 13 | 13 | 14 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 41 | 47 | 51 | 58 | 53 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 1 | 2 | 1 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 2 | 2 | 3 | 2 | 2 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2 | 2 | 2 | 2 | 2 |
Total Current Liabilities | 6 | 6 | 7 | 6 | 6 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 15 | 15 | 15 | 15 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 21 | 21 | 22 | 22 | 22 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 270 | 269 | 269 | 269 | 261 |
Retained Earnings | -267 | -261 | -258 | -251 | -247 |
Other Equity | 17 | 17 | 17 | 17 | 17 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 20 | 25 | 29 | 36 | 31 |
Total Liabilities & Shareholder's Equity | 41 | 47 | 51 | 58 | 53 |
Total Common Equity | 20 | 25 | 29 | 36 | 31 |
Shares Outstanding | 4.10 | 4.10 | 4.10 | 4.10 | 4.10 |
Book Value Per Share | 4.86 | 6.19 | 7.00 | 8.75 | 7.59 |